Dr. Marcela V. Maus

Dr. Marcela V. Maus, MD, PhD, is an internationally recognized physician–scientist specializing in cellular immunotherapy and cancer immunology. She is Director of the Cellular Immunotherapy Program at Massachusetts General Hospital, holds the Paula J. O’Keeffe Endowed Chair, and serves as Professor of Medicine at Harvard Medical School. Dr. Maus earned her MD and PhD in immunology from the University of Pennsylvania, completed her residency in internal medicine at the Hospital of the University of Pennsylvania, and pursued fellowship training in hematology and oncology at Memorial Sloan Kettering Cancer Center. She is board-certified in Internal Medicine, Hematology, and Medical Oncology and is widely acknowledged for her leadership in the development of CAR-T cell therapies.

A pioneer in the field of engineered T cell therapies, Dr. Maus has led translational and clinical research advancing CAR-T cells for hematologic malignancies and extending cellular immunotherapy approaches to solid tumors such as glioblastoma and pancreatic cancer. Her laboratory has produced foundational insights into T cell receptor signaling, persistence, and mechanisms of tumor resistance, which have shaped next-generation therapeutic designs. She has authored numerous high-impact publications, led early-phase clinical trials, and contributed to national initiatives that are setting standards for immunotherapy development and application.

In addition to her scientific and clinical leadership, Dr. Maus is a dedicated educator and mentor. She has trained numerous physician–scientists and fellows in immuno-oncology, fostering the next generation of leaders in translational medicine. She serves in leadership positions within organizations such as the American Society of Gene & Cell Therapy and has advised national working groups on cellular therapy. Through her commitment to clinical innovation, laboratory discovery, and mentorship, Dr. Marcela Maus continues to drive progress in cellular immunotherapy and expand treatment options for patients with cancer worldwide.